Celldex Therapeutics Inc (NASDAQ: CLDX) suffers from exceptional negative changes in investment behavior: the stock’s recent price decline challenged its longer term uptrend, its shorter term price trend turned down, and the stock fell on very heavy volume.
Recent minimal negative changes in fundamentals have impacted Celldex Therapeutics Inc (NASDAQ: CLDX): the stock’s power rating fell below 50.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, CLDX is expected to continue to be a modest Value Builder.
Celldex Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing complementary signals. Celldex Therapeutics has a slightly negative Power Rating of 32 and a very low Appreciation Score of 7, and the Lowest Value Trend Rating results.
Recent Price Action
Celldex Therapeutics Inc (NASDAQ: CLDX) stock suffered a large decline of -8.8% on 9/26/24. The stock closed at $32.86. Moreover, this decline was accompanied by exceptionally high trading volume at 295% of normal. The stock has performed in line with the market over the last nine months and has declined -21.5% during the last week.
Be the first to comment